Evaluation of combinatorial vaccines against anthrax and plague in a murine model

Vaccine

Volumn 25, Issue 24, 2007, Pages 4747-4754

  DuBois, Amanda B ^a   Freytag, Lucy C ^a   Clements, John D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anthrax; Combinatorial vaccines; Plague

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PLAGUE VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; LUNG LAVAGE; NONHUMAN; PLAGUE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT PROTEINS; VACCINES, COMBINED;

EID: 34248579294     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.048     Document Type: Article

References (43)

1. Flick-Smith H.C., Eyles J.E., Hebdon R., Waters E.L., Beedham R.J., Stagg T.J., et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 70 4 (2002) 2022-2028
2. Gaur R., Gupta P.K., Banerjea A.C., and Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 20 21-22 (2002) 2836-2839
3. Glynn A., Freytag L.C., and Clements J.D. Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 23 16 (2005) 1957-1965
4. Glynn A., Roy C.J., Powell B.S., Adamovicz J.J., Freytag L.C., and Clements J.D. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73 8 (2005) 5256-5261
5. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 11-12 (1998) 1131-1137
6. Kenney R.T., Yu J., Guebre-Xabier M., Frech S.A., Lambert A., Heller B.A., et al. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis 190 4 (2004) 774-782
7. Morton M., Garmory H.S., Perkins S.D., O'Dowd A.M., Griffin K.F., Turner A.K., et al. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine 22 20 (2004) 2524-2532
8. Singh Y., Ivins B.E., and Leppla S.H. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect Immun 66 7 (1998) 3447-3448
9. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., and Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 2 (1986) 356-363
10. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12 3-4 (1995) 223-230
11. Williamson E.D., Sharp G.J., Eley S.M., Vesey P.M., Pepper T.C., Titball R.W., et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 14 17-18 (1996) 1613-1619
12. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., and Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 116 1 (1999) 107-114
13. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker III J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 191 2 (2005) 278-288
14. Titball R.W., and Williamson E.D. Vaccination against bubonic and pneumonic plague. Vaccine 19 30 (2001) 4175-4184
15. Titball R.W., and Williamson E.D. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4 6 (2004) 965-973
16. Dixon T.C., Meselson M., Guillemin J., and Hanna P.C. Anthrax. N Engl J Med 341 11 (1999) 815-826
17. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Plague as a biological weapon: medical and public health management. Working group on civilian biodefense. JAMA 283 17 (2000) 2281-2290
18. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280 5364 (1998) 734-737
19. Vitale G., Pellizzari R., Recchi C., Napolitani G., Mock M., and Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun 248 3 (1998) 706-711
20. Leppla S.H. A dominant-negative therapy for anthrax. Nat Med 7 6 (2001) 659-660
21. Mock M., and Fouet A. Anthrax. Annu Rev Microbiol 55 (2001) 647-671
22. Cote C.K., Rossi C.A., Kang A.S., Morrow P.R., Lee J.S., and Welkos S.L. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38 5-6 (2005) 209-225
23. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 Pt 6 (2001) 1677-1685
24. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., Worsham P., et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21 5 (2005) 1490-1510
25. Belyakov I.M., Hel Z., Kelsall B., Kuznetsov V.A., Ahlers J.D., Nacsa J., et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 7 12 (2001) 1320-1326
26. Cardenas-Freytag L., Cheng E., Mayeux P., Domer J.E., and Clements J.D. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun 67 2 (1999) 826-833
27. Cheng E., Cardenas-Freytag L., and Clements J.D. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18 1-2 (2000) 38-49
28. Dickinson B.L., and Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63 5 (1995) 1617-1623
29. Losonsky G.A., Kotloff K.L., and Walker R.I. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine 21 5-6 (2003) 562-565
30. Yuan L., Iosef C., Azevedo M.S., Kim Y., Qian Y., Geyer A., et al. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs. J Virol 75 19 (2001) 9229-9238
31. Chong C., Friberg M., and Clements J.D. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine 16 7 (1998) 732-740
32. Gerber S., Lane C., Brown D.M., Lord E., DiLorenzo M., Clements J.D., et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 75 10 (2001) 4752-4760
33. Kotloff K.L., Sztein M.B., Wasserman S.S., Losonsky G.A., DiLorenzo S.C., and Walker R.I. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 69 6 (2001) 3581-3590
34. Morris C.B., Cheng E., Thanawastien A., Cardenas-Freytag L., and Clements J.D. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine 18 18 (2000) 1944-1951
35. Griffin K., Bedford R., Townson K., Phillpotts R., Funnell S., Morton M., et al. Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine. FEMS Immunol Med Microbiol 43 3 (2005) 425-430
36. Gil A., Gonzalez A., Dal-Re R., and Calero J.R. Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440 EL.U.). A controlled study in adults. Vaccine 14 11 (1996) 1028-1030
37. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 5 (1998) 2093-2098
38. Eskola J., Olander R.-M., Hovi T., Litmanen L., Peltola S., and Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. The Lancet 348 9043 (1996) 1688
39. Gupta R.K., Anderson R., Cecchini D., Rost B., Xu J., Gendreau K., et al. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine. Biologicals 27 2 (1999) 167-176
40. McVernon J., Andrews N., Slack M.P., and Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 9368 (2003) 1521-1523
41. Frey S., Dagan R., Ashur Y., Chen X.Q., Ibarra J., Kollaritsch H., et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis 180 6 (1999) 2018-2022
42. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., and McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170 11 (2003) 5636-5643
43. Nakajima R., Motin V.L., and Brubaker R.R. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 63 8 (1995) 3021-3029